Clinical trials: Ragweed Allergy
Allergy
Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
- Trial name
- NCT01353079
- Testing
- Short Ragweed Pollen Allergenic Extract
- Where
- United States
- Volunteers
- 429 people
- Sponsor
- Greer Laboratories
Allergic Rhinitis
Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies
The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration
- Trial name
- NCT00599872
- Testing
- Standardized Ragweed Allergenic Extract
- Where
- 30 sites in United States
- Volunteers
- 430 people
- Sponsor
- Greer Laboratories
Seasonal Allergic Rhinitis
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
Finding out how fast azelastine nasal spray works in subjects with hay fever.
- Trial name
- GEYSER (NCT00561717)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Bayer
Seasonal Allergic Rhinitis, Asthma
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.
- Trial name
- NCT02061670
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Circassia Limited
Ragweed Allergy
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
The aim of the study is to identify changes in potential biomarkers after peptide immunotherapy for that may subsequently be developed as biomarkers that correlate with clinical efficacy.
- Trial name
- NCT01361412
- Testing
- ToleroMune Ragweed
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Circassia Limited
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Ragweed MATA MPL
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis…
- Trial name
- NCT00423787
- Testing
- Ragweed MATA MPL
- Where
- 76 sites in United States, Canada
- Volunteers
- 993 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S